coli (AIEC) in Crohn’s disease Inflamm Bowel Dis 2009, 15:872–82

coli (AIEC) in Crohn’s disease. Inflamm Bowel Dis 2009, 15:872–82.CrossRefPubMed 15. Barnich N, Carvalho FA, Glasser

AL, Darcha C, Jantscheff P, Allez M, Peeters H, Bommelaer G, Desreumaux P, Colombel JF, et al.: CEACAM6 acts as a receptor for adherent-invasive E. coli DMXAA clinical trial , supporting ileal mucosa colonization in Crohn disease. J Clin Invest 2007, 117:1566–1574.CrossRefPubMed 16. Bruewer M, Samarin S, Nusrat A: Inflammatory bowel disease and the apical junctional complex. Ann N Y Acad Sci 2006, 1072:242–252.CrossRefPubMed 17. Weber CR, Turner JR: Inflammatory bowel disease: is it really just another break in the wall? Gut 2007, 56:6–8.CrossRefPubMed 18. Wyatt J, Vogelsang H, Hubl W, Waldhoer T, Lochs H: Intestinal permeability and the prediction of relapse in Crohn’s disease. Lancet 1993, 341:1437–1439.CrossRefPubMed 19. D’Inca R, Annese V, di Leo V, Latiano A, Quaino V, Abazia C, Vettorato MG, Sturniolo GC: Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn’s disease. Aliment Pharmacol Ther 2006, 23:1455–1461.CrossRefPubMed 20. Prasad S, Mingrino R, Kaukinen K, Hayes KL, Powell RM, MacDonald TT, Collins JE: Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic Lonafarnib datasheet epithelial cells. Lab Invest 2005, 85:1139–1162.CrossRefPubMed 21. Zeissig S, Burgel N, Gunzel D, Richter J, Mankertz J, Wahnschaffe Enzalutamide in vivo U, Kroesen AJ, Zeitz M, Fromm M, Schulzke JD: Changes in expression

and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction PD184352 (CI-1040) in active Crohn’s disease. Gut 2007, 56:61–72.CrossRefPubMed 22. Amieva MR, Vogelmann R, Covacci A, Tompkins LS, Nelson WJ, Falkow S: Disruption of the epithelial apical-junctional complex by Helicobacter pylori CagA. Science 2003, 300:1430–1434.CrossRefPubMed 23. Johnson-Henry KC, Donato KA, Shen-Tu G, Gordanpour M, Sherman PM:Lactobacillus rhamnosus strain GG prevents enterohemorrhagic Escherichia coli O157:H7-induced changes in epithelial barrier function. Infect Immun 2008, 76:1340–1348.CrossRefPubMed 24. Zareie M, Riff J, Donato

K, McKay DM, Perdue MH, Soderholm JD, Karmali M, Cohen MB, Hawkins J, Sherman PM: Novel effects of the prototype translocating Escherichia coli , strain C25 on intestinal epithelial structure and barrier function. Cell Microbiol 2005, 7:1782–1797.CrossRefPubMed 25. Raimondi F, Santoro P, Barone MV, Pappacoda S, Barretta ML, Nanayakkara M, Apicella C, Capasso L, Paludetto R: Bile acids modulate tight junction structure and barrier function of Caco-2 monolayers via EGFR activation. Am J Physiol Gastrointest Liver Physiol 2008, 294:G906–913.CrossRefPubMed 26. Howe KL, Reardon C, Wang A, Nazli A, McKay DM: Transforming growth factor-beta regulation of epithelial tight junction proteins enhances barrier function and blocks enterohemorrhagic Escherichia coli O157:H7-induced increased permeability. Am J Pathol 2005, 167:1587–1597.

Comments are closed.